To view or add a comment, sign in The GLP-1 market has moved past proof of demand. What matters now is whether your infrastructure can survive success In the last 12 months, weve seen the same pattern repeat: *Clinics grow fast *Prescribing volume increases *Regulators tighten *Fulfilment starts to wobble Thats usually when people realise their pharmacy partner was designed for small numbers - not sustained, regulated growth GLP-1s have moved on This isnt early-adopter territory anymore If your model relies on: - Manual workarounds - Fragile dispensing processes - Partners who are reacting to regulation instead of staying ahead of it it will eventually become the constraint on your growth The next phase of this market will reward operators who treat GLP-1s as infrastructure, not just medication Systems that hold under pressure will quietly outperform brands that dont Most clinics will only address this once something breaks The smart ones are doing it earlier If GLP-1s matter to your business this year, the uncomfortable question is simple: is your setup actually built to scale - or just to start

Weight Loss Clinic Serving Miami, Aventura, North Miami & Hialeah Struggling to lose weight despite diet and exercise
Moreover, agrin-treated pericytes exhibited elevated levels of ROS and Fe 2+ , along with reduced expression of GPX4 and FTH1, thereby promoting ferroptosis, suppressing pericyte proliferation, and compromising blood-brain barrier function
Some risk factors for vitamin B12 deficiency include: Old age Atrophic gastritis (a condition that damages the stomach lining) Certain health conditions and medications A vegan or vegetarian diet How Do I Know If My Vitamin B12 Levels Are Low
Capsular fibrosis: a review of prevention methods and management